Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.47 |
| ▸ | GRM8 | O00222 | 6/20 | 0.47 |
| ▸ | GRM6 | O15303 | 3/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL10755723 | 0.95 | GRM4 (0.52) | GPR35GSRGRM4GRM8GRM6 | |
| Lysine SCHEMBL28251933 | 0.92 | GSR (0.54) | GPR35GSRGRM4GRM8GRM6 | |
| Lysine SCHEMBL9555446 | 0.92 | GPR35 (0.47) | GPR35GSRGRM4GRM8GRM6 | |
| Lysine SCHEMBL2678982 | 0.89 | GSR (0.53) | GSRGRM4GRM8GRM6GRM7 | |
| Lysine SCHEMBL7542135 | 0.87 | GRM8 (0.56) | GPR35GSRGRM4GRM8GRM6 | |
| Lysine SCHEMBL7548602 | 0.87 | GRM8 (0.56) | GPR35GSRGRM4GRM8GRM6 | |
| Lysine SCHEMBL12478274 | 0.85 | GSR (0.46) | GSRGRM4GRM8GRM6MMP2 | |
| Lysine SCHEMBL10754341 | 0.81 | GRM4 (0.49) | GSRGRM4GRM8GRM6 | |
| Cystine SCHEMBL6937787 | 0.81 | GPR35 (0.60) | GPR35GRM4GRM8GRM6GRM7 | |
| Lysine SCHEMBL20303615 | 0.81 | GSR (0.53) | GSRGRM4GRM8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | claimed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | claimed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | claimed |
| US-20030059847-A1 | Combinatorial protease substrate libraries | IRM, LLC (BM) | 2003-03-27 | — | — | US | claimed |
| US-10456451-B2 | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | MESOBLAST INTERNATIONAL SÀRL (CH) | 2019-10-29 | — | — | US | disclosed |
| WO-2018136939-A1 | EVOLVED PROTEASES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20160375100-A1 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE | MESOBLAST UK LIMITED (GB) | 2016-12-29 | — | — | US | disclosed |
| US-9308277-B2 | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage | MESOBLAST INTERNATIONAL SÀRL (CH) | 2016-04-12 | — | — | US | disclosed |
| US-8931490-B2 | Systems and methods for nanomagnetic actuation of molecular cell signaling | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20110224139-A1 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE | Provasculon, Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011106234-A1 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE | Provasculon, Inc. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100203143-A1 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2008156904-A2 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20040009911-A1 | Hepsin substrates and prodrugs | IRM, LLC (BM) | 2004-01-15 | — | — | US | disclosed |
| WO-2003064620-A2 | HEPSIN SUBSTRATES AND PRODRUGS | IRM, LLC (BM) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003029823-A1 | COMBINATORIAL PROTEASE SUBSTRATE LIBRARIES | IRM LLC (BM) | 2003-04-10 | — | — | WO | disclosed |
| US-20030059847-A1 | Combinatorial protease substrate libraries | IRM, LLC (BM) | 2003-03-27 | — | — | US | disclosed |
| US-5633140-A | HIGH SPEED COLORIMETRIC ANALYSIS | Dr agerwerk Aktiengesellschaft (DE) | 1997-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224139-A1 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE | CXCL12, CTSC, CTSG | GPR35 4065/4885GSR 2890/4885GRM4 3832/4885 |
| US-20160375100-A1 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE | CXCL12, CTSC, CTSG | GPR35 4065/4885GSR 2890/4885GRM4 3832/4885 |
| US-20040009911-A1 | Hepsin substrates and prodrugs | HPN, SPR, TMPRSS15 | GPR35 1993/4885GSR 2880/4885GRM4 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.